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Abstract
Aims/hypothesis Non-invasive imaging of beta cells is a
much-needed development but is one that faces significant
biological and technological hurdles. A relevant imaging
method should at least allow for an evaluation over time of
the mass of beta cells under physiological and pathological
conditions, and for an assessment of novel therapies. We,
therefore, investigated the ability of a new MRI probe to
repeatedly measure the loss of beta cells in a rodent model.
Methods We developed an innovative nanoparticle probe that
targets the glucagon-like peptide 1 receptor, and can be used
for both fluorescence imaging and MRI. Using fluorescence,
we characterised the specificity and biodistribution of the
probe. Using 1.5T MRI, we longitudinally imaged the chang-
es in insulin content in male and female mice of the RIP-DTr
strain, which mimic the changes expected in type 1 and type 2
diabetes, respectively.
Results We showed that this probe selectively labelled beta
cells in situ, imaged in vivo native pancreatic islets and
evaluated their loss after diphtheria toxin administration, in a
model of graded beta cell deletion. Thus, using clinical MRI,
the probe quantitatively differentiates, in the same mouse
strain, between female animals featuring a 50% loss of beta
cells and the males featuring an almost complete loss of beta
cells.
Conclusions/interpretation The approach addresses several
of the hurdles that have so far limited the non-invasive imag-
ing of beta cells, including the potential to repeatedly monitor
the very same animals using clinically available equipment,
and to differentiate graded losses of beta cells.
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fluorophore Alexa647
PET Positron emission computed tomography
RIP-DTr Rat insulin promoter-DT receptor
Sulfo-SMCC Sulfosuccinimidyl-4-(N-maleimidomethyl)
cyclohexane-1-carboxylate
SPECT Single photon emission computed
tomography
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-014-3442-2) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
L. Vinet (*) : S. Lamprianou : F. Thorel : P. L. Herrera
Department of Genetic Medicine and Development,
University of Geneva, Geneva, CMU, 1 rue Michel-Servet,
CH-1211 Geneva 4, Switzerland
e-mail: laurent.vinet@unige.ch
A. Babič :N. Lange
School of Pharmaceutical Sciences, University of Geneva,
University of Lausanne, Geneva, Switzerland
X. Montet
Department of Radiology, Geneva University Hospital,
Geneva, Switzerland
P. Meda
Department of Cell Physiology and Metabolism,





TSE Turbo spin echo
USPIO Ultrasmall superparamagnetic particles
of iron oxide
Introduction
The non-invasive, repeated in vivo imaging of beta cells,
which are central players in most forms of diabetes [1], is
highly desirable from both a research and a clinical standpoint.
The method should allow for the evaluation of the normal
mass and function of beta cells, of their spontaneous changes
with time under physiological and pathological conditions and
of the effects of candidate therapies [2]. The development of
such an imaging method, which is complicated by a combi-
nation of anatomical, biological and technical hurdles [2, 3],
may be eased by the use of sensitive and beta cell-specific
probes. The glucagon-like peptide 1 receptor (GLP-1r), which
has become an important target in the treatment of type 2
diabetes [4], is emerging as a potential target for such probes,
because of its high expression in beta cells [5]. The endoge-
nous ligand of the GLP-1r (i.e. GLP-1), induces the release of
insulin in a glucose-dependent manner and promotes beta cell
proliferation in adult rodents [6]. The long-acting analogue
exendin-4 also binds to the extracellular domain of GLP-1rs
with picomolar affinity [7], and exendin derivatives have been
developed for fluorescence, nuclear and magnetic resonance
imaging of beta cells [8–11], transplanted islets [12, 13] and
insulinomas [14–16] and for screening of patients with type 1
diabetes [17].
The position of the pancreas within the abdomen and the
dispersion of its small endocrine islets imply the need for a
deep-penetrating and highly sensitive approach. Therefore,
most of these studies have relied on nuclear medical imaging
methods (positron emission computed tomography [PET] and
single photon emission computed tomography [SPECT]), in
spite of the limited spatial resolution of these methods and
their potential safety issues [2, 3]. Specifically, the radiation
dosemight be a potential limiting factor in longitudinal studies
of healthy volunteers and diabetic patients, as pointed out in
several studies with radiolabelled exendin [11, 14, 18, 19]. In
the search for alternatives, several studies have investigated
MRI [20–22], a method that does not involve ionising radia-
tion. The modality provides for an unsurpassed anatomical
visualisation of soft tissues, including individual islets in
experimental models when high magnetic fields are used
[21, 23]. Still, MRI has a significantly lower sensitivity than
either PET or SPECT, and hardly allows for an absolute
quantitative evaluation of the signal [2, 3]. The development
of targeted ultrasmall superparamagnetic particles of iron
oxide (USPIO) [24–26], nanoparticles that modify the mag-
netic resonance signal [27–29], may help to ameliorate some
of these limitations. Thus, a recent study has documented that
such MRI probes permit the in vivo differentiation of
normoglycaemic from hyperglycaemic animals in a rodent
model of type 1 diabetes [30]. To assess whether this approach
could be adapted to the repeated, sequential monitoring of
individual animals, specifically under conditions of a partial
loss of beta cells such as is expected in type 2 diabetic patients
[31], we developed a new, dual modality nanoparticle probe
that targets the GLP-1r and that is suitable for both fluores-
cence and MRI. Here, we show that this probe permits the
following: (1) selective labelling of beta cells in situ; (2)
imaging of native pancreatic islets in vivo; (3) repeated and
longitudinal monitoring of individual animals and (4) differ-
entiation of animals with a partial loss of beta cells from those
with an almost complete loss.
Methods
Synthesis of the exendin–nanoparticle probe A Cys-1 modi-




Ser) was synthesised by GeneCust Europe (Dudelange,
Luxembourg). Molday ION C6Amine iron oxide nanoparti-
cles, featuring ~9,000 iron atoms per particle and a 35 nm
diameter (Biopal, Worcester, MA, USA), were reacted with
the succinimidyl ester of Alexa Fluor 647 (LifeTechnologies
Europe, Zug, Switzerland) to obtain a ratio of 20 fluoro-
chrome molecules/nanoparticle (Np647). Np647 was reacted
with sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-
1-carboxylate (Sulfo-SMCC; Thermo-Scientific, Rockford,
IL, USA) to obtain maleimide-activated Np647, which was
reacted with ExCys1 (electronic supplementary material
[ESM] Fig. 1). The resulting Np647–ExCys1 conjugates were
purified by size exclusion PD10 chromatography. The
peptide-to-iron ratio (~25 ExCys1/nanoparticle), was deter-
mined by bicinchoninic acid protein assay, using an exendin
standard curve in the presence of Np647. To control the
specificity of the Np647–ExCys1 probe, we tested the follow-
ing: (1) a non-targeted probe (Np647–ExScra) produced by
reacting the maleimide-activated Np647 with a Cys-1 scram-
bled peptide (ExScra) of exendin-4 (GeneCust Europe) and
(2) Np647–ExCys1 (5 μg i.v.) co-injected with free exendin-4
(750μg s.c.; 12 h later a second s.c. injection of free exendin-4
was given to maintain a large [~100-fold] molar excess of free
exendin-4 over the equivalent Np647–ExCys1 dose).
In vitro studies Cells of the MIN6, Panc-1 and HeLa lines
were cultured as previously reported [32]. At the time of the
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experiments, cultures had a density of about 106 cells/ml. To
assess the specificity of the cell labelling, medium was re-
moved and cells were rinsed twice in PBS and then exposed at
37°C to 50 μg/ml Np647–ExCys1 added to a Krebs Ringer
bicarbonate medium. Thirty minutes later, the cells were
rinsed twice in PBS and examined under an Axiophot fluo-
rescence microscope (Zeiss, Oberkochen, Germany) equipped
with filters for Alexa 647.
To assess whether Np647–ExCys1 affected the viability of
MIN6 cells, cultures were exposed for 24 h to 50 μg/ml
Np647–ExCys1 added directly to DMEM (Gibco-
LifeTechnologies Europe, Zug, Switzerland). Cells were then
tested in a thiazolyl blue tetrazolium bromide (MTT) assay
(M2128; Sigma-Aldrich, St Louis, MO, USA), and for
glucose-induced insulin secretion (for details, see ESM
Methods).
Rat insulin promoter-diphtheria toxin receptor mice Mice
were housed in a conventional animal facility and all animal
experiments were conducted as per the protocols authorised
by our institutional and State authorities (Authorisation no.
1034/3550/2).
Rat insulin promoter-diphtheria toxin receptor (RIP-DTr)
mice were generated as reported [33]. Briefly, the transgene
containing an insulin promoter and the diphtheria toxin (DT)
receptor coding sequence (RIP-DTr) was targeted to the Hprt
locus of the X chromosome. Thus, in this model, DT admin-
istration leads to a parallel loss of insulin content and beta
cells, which is partially due to the random X inactivation (on
average 50%) in hemizygous female mice and nearly com-
plete ablation in male mice.
To evaluate the total insulin content of the pancreas, whole
glands were carefully dissected and extracted in acid-ethanol
for 24 h, as reported [34, 35]. Pancreas insulin content was
evaluated using a rodent insulin ELISA kit (Mercodia,
Uppsala, Sweden) according to the manufacturer’s instructions.
Biodistribution of the exendin–nanoparticle probe Male
RIP-DTr mice [33] were injected through the retro-orbital
venous plexus with 5 μg/(g body weight) of either Np647–
ExCys1 or Np647–ExScra or were co-injected with 5 μg
Np647–ExCys1 and two subcutaneous doses of 750 μg free
exendin-4 at a 12 h interval (the subcutaneous route was
chosen to slow down the absorption of the free peptide into
the circulation).
Mice were killed 24 h later, and immediately perfused via
the left ventricle, first with 10ml 0.9%NaCl (154mmol/l) and
then with 10 ml 4% paraformaldehyde in 0.1 mol/l phosphate
buffer at 37°C. The pancreas, liver, spleen, kidneys, lung,
duodenum and heart were harvested and fixed in paraformal-
dehyde for 2 h at 4°C. The organs were rinsed for 2 h in
phosphate buffer at 4°C, and their fluorescence recorded with
an IVIS Spectrum (PerkinElmer, Waltham, MA, USA)
equipped with filters for Alexa 647. Corresponding organs
from mice injected with Np647–ExCys1 and Np647–ExScra,
as well as from mice injected with Np647–ExCys1 with and
without an excess of exendin-4, were imaged in parallel. To
differentiate between tissue autofluorescence and fluorescence
due to the A647 fluorochrome, the organs were excited using
535, 570, 605 and 640 nm excitation filters and fluorescence
was recorded using a 680 nm emission filter. Spectral
unmixing was performed with the Living Image 4.3.1 software
(PerkinElmer, Waltham, MA, USA) and fluorescence signals
(expressed as average radiant efficiency, 107 [p s–1 cm–2 sr–1]/
[μW/cm2]) were quantified on the unmixed image after sup-
pression of the autofluorescence levels.
The fixed pancreas, liver, spleen and kidneys were also
rinsed for 15 h in 30% sucrose, embedded in OCT compound
(Sakura Finetek, Torrance, CA, USA), and cryo-sectioned at
7 μm thickness. Sections were mounted and examined by
fluorescence microscopy. Pancreas sections were
immunolabelled using either guinea pig antibodies against
insulin (Ventrex Laboratories, Portland, ME, USA), diluted
1/200, mouse antibodies against glucagon (Sigma-Aldrich),
diluted 1/2,000, or rabbit antibodies against exendin-4
(Abcam, Cambridge, UK), diluted 1/100. Secondary antibod-
ies were anti-guinea pig antibodies coupled to Dylight 405
(Jackson Immunoresearch Laboratories, WestGrove, PA,
USA) diluted 1/800, anti-mouse antibodies coupled to
tetramethylrhodamine (SouthernBiotech, Birmingham, AL,
USA), diluted 1/500, and anti-rabbit antibodies coupled to
A488 (Molecular Probes, Eugene, OR, USA), diluted 1/500,
for insulin, glucagon and exendin-4 immunolabelling,
respectively. Coverslips were placed over the sections
and the sections were photographed with an Axiophot
fluorescence microscope (Zeiss).
MRI Three-to-four-months-old male and female mice of the
RIP-DTr strain [33, 36] were tested before and after DT
administration.Micewere initially imaged before the injection
of a probe to obtain a baseline T2 value (ESM Fig. 2). The
mice were then injected through the retro-orbital venous plex-
us with 5 mg/kg Np647–ExCys1 and were immediately im-
aged (time 0) for evaluation of the vascular volume fraction,
which reflects the blood perfusion of the pancreas. A third
MRI scan was performed 24 h later, to allow for the evaluation
of the probe accumulation. One week after this first imaging
session, the same mice were given three intraperitoneal injec-
tions of 125 ng DT (injections administered on days 7, 9 and
11; ESM Fig. 2) and were monitored for non-fasting blood
glucose by measuring tail-vein blood samples with a glucose
meter. One week after the beginning of the DTadministration,
the mice underwent a second imaging session, as per the
protocol mentioned above (ESM Fig. 2). Female mice
underwent a similar, third MRI session 3 months after the
DT injection (ESM Fig. 2).
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To test whether the probe accumulation reflected the insu-
lin content of the pancreas, a group of RIP-DTr mice was
killed for pancreas sampling and determination of insulin
content, immediately after a single MRI session.
All magnetic resonance images were acquired on a 1.5 T
clinical scanner (Philips Medical System, Best, the Nether-
lands), equipped with a surface coil (Ø=47 mm). Coronal T2
maps were generated using a three-dimensional turbo spin
echo (TSE) sequence with the following parameters: repeti-
tion time (TR)=145 ms; six different echo time (TE) values
ranging from 9 to 54 ms; flip angle=90°; matrix size=116×
83; number of average=1; field of view=60×41; slice thick-
ness=0.5 mm. A total of 102 sequential coronal images were
obtained to cover the entire pancreatic region. All images were
analysed with the dicom viewer Osirix (Pixmeo SARL,
Bernex, Switzerland). Regions of interest for analyses were
manually defined on three consecutive MRI slices of each
pancreas. Probe accumulation was given by loge (T2 before
nanoparticle injection/T2 24 h after nanoparticle injection)
[27, 29].
Statistical analysis Data were analysed using either paired or
unpaired Student’s t test, assuming a two-tailed distribution, or
two-way ANOVA, followed by the Bonferroni multiple com-
parison post hoc test (GraphPad Prism 5; GraphPad Software,
La Jolla, CA, USA). A p value of ≤0.05 was considered
statistically significant.
Results
The Np647–ExCys1 probe targets insulin-containing cells,
and is not toxic in vitro Thirty minutes after the addition of
50 μg/ml Np647–ExCys1 to the culture medium of MIN6
cells, which express insulin and GLP-1r, fluorescence micros-
copy revealed co-staining of most cells for exendin-4 and
Np647–ExCys1 (Fig. 1a). Under identical conditions, no such
staining was observed in cultures of Panc-1 and HeLa cells,
neither of which express insulin or GLP-1r (Fig. 1a). After
24 h exposure to 50 μg/ml of either Np647–ExCys1 or
Np647–ExScra, the viability of MIN6 cells was not altered,
as indicated by an MTT assay (Fig. 1b) and also by the
retention of a control glucose-induced insulin secretion
(Fig. 1c).
The Np647–ExCys1 probe targets in vivo several organs
expressing GLP-1rs Twenty-four hours after intravenous in-
jection, the Np647–ExCys1 probe distributed in the pancreas
(Fig. 2 a, b), and other organs expressing GLP-1rs, including
lung, duodenum, kidney and heart (Fig. 2b). In these organs
the accumulation of the non-targeted Np647–ExScra
probe was lower. In contrast, the accumulation of the
Np647–ExCys1 and the Np647–ExScra probes was
comparable in liver and spleen, which non-specifically take
up nanoparticles (Fig. 2b). An excess of free exendin-4 also
significantly reduced the accumulation of Np647–ExCys1 in
the organs expressing GLP-1rs, but not in liver and spleen
(ESM Fig. 3a).
The Np647–ExCys1 probe targets insulin-containing cells
in vivo Twenty-four hours after the intravenous injection of
Np647–ExCys1 in normoglycaemic mice of the RIP-DTr
strain, fluorescence microscopy revealed that the nanoparti-
cles labelled most insulin-containing beta cells, but not the
glucagon-containing alpha cells, and the surrounding acinar
cells (Fig. 3a). The Np647–ExCys1 probe distributed in a
similar manner to the exendin-4 peptide (ESM Fig. 4a). The
beta cell labelling by nanoparticles was not observed when
mice were injected with the Np647–ExScra probe (Fig. 3b) or
with the Np647–ExCys1 probe in the presence of an excess
exendin-4 (ESM Fig. 3d).
The Np647–ExCys1 probe decreases the enhancement of
T2-weighted magnetic resonance images Immediately after
the intravenous injection of either Np647–ExCys1 or
Np647–ExScra (t=0), the T2 of pancreas was significantly
reduced compared with the baseline value measured before
the injection (Fig. 4 a, b), consistent with a similar vascular
distribution of the two probes. For Np647–ExScra, this
change was reverted 24 h later, because of the washout of
the control probe (Fig. 4b). In contrast, it was maintained for
Np647–ExCys1 (Fig. 4a), consistent with the binding of the
probe to the GLP-1r of beta cells. Comparison of the T2
values measured before and 24 h after the probe injection
(Fig. 4c), revealed a larger pancreatic accumulation of the
Np647–ExCys1 than of the Np647–ExScra probe (Fig. 4d).
The accumulation of the Np647–ExCys1 probe was also
decreased in the presence of an excess of free exendin-4
(ESM Fig. 3b).
The Np647–ExCys1 probe differentiates graded losses of
insulin in RIP-DTr mice We used the Np647–ExCys1 probe
to repeatedly monitor the same RIP-DTr mice before and after
DT administration (ESM Fig. 2). Prior to this administration,
male and female RIP-DTr mice showed a similar level of
pancreatic accumulation of the probe (Fig. 5). One week after
DT administration, the same imaging protocol revealed a
significant drop in the probe accumulation in all male mice
(p<0.01) and most female mice (p<0.05; ESM Figs 5 and 6).
This drop was significantly higher (p<0.05) in male mice
(average 74%) than in female mice (average 42%; Fig. 5),
which associated with a sex difference in beta cells (Fig. 6)
and insulin content (ESM Fig. 5a). Thus, whereas female
RIP-DTr mice featured a sizeable number of beta cells
(Fig. 6a) and a relatively high insulin content (on average
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63% of the control levels; ESM Fig. 5a) up to 3 months after
the DTadministration, male mice featured a rapid, and close to
complete, loss of both beta cells (Fig. 6b) and insulin (0.4% of
control levels; ESM Fig. 5a). Plotting the data from a group of
mice in which the pancreases were sampled immediately after
the MRI session revealed a significant (p<0.01) correlation
(R=0.834), between insulin content and the accumulation of
the probe in the pancreas (ESM Fig. 5b).
Discussion
We developed a novel probe which couples USPIOs to a
modified exendin peptide in a different manner to that previ-
ously reported [30]. The new probe allows for a specific
conjugation of the peptide to the iron oxide nanoparticles,
while preserving the binding motif of exendin-4 for the
GLP-1r [8, 37, 38]. Here, we show that the new probe, which
does not alter the viability or secretory function of insulin-
producing cells in vitro, selectively targets the vast majority of
the endogenous beta cells in situ, even though it also binds to
other abdominal organs expressing GLP-1rs. The specificity
of the probe for these receptors was demonstrated ex vivo by a
decreased fluorescence signal in the organs expressing
GLP-1rs [39, 40], using either nanoparticles tagged with an
exendin-4 scrambled peptide or exendin-4-targeted nanopar-
ticles in the presence of an excess of free exendin-4. An
exception was the heart, in which the signal was not decreased
in the presence of an excess of exendin-4, possibly because
the immediate and large blood perfusion of the organ resulted
in a probe availability for which the free peptide could not
compete. In addition, the beta cell specificity of the pancreatic
MRI signal was demonstrated in vivo by a decreased probe
accumulation in the following situations: (1) when using
nanoparticles tagged with the scrambled peptide, a widely
used control in nanoparticle studies [24–26, 41, 42]; (2) when











































































Fig. 1 (a) Fluorescence
microscopy of MIN6, Panc-1 and
HeLa cells after 30 min
incubation in the presence of
Np647–ExCys1. Scale bar,
50 μm. (b) MTT assay on MIN6
cells exposed for 24 h to exendin-
4, Np647–ExCys1 or Np647–
ExScra (n=3 per condition; each
condition was expressed as the
fold change relative to control set
to 1). (c) Glucose-stimulated
insulin secretion of MIN6 cells
exposed for 24 h to exendin-4,
Np647–ExCys1 or Np647–
ExScra (n=6 per condition). Data
are mean + SEM. *p<0.05 and


























































Fig. 2 (a) Ex vivo fluorescence images of pancreas, 24 h after the
intravenous injection of either Np647–ExCys1 or Np647–ExScra. (b)
Semi-quantitative analysis of fluorescence 24 h after the intravenous
injection of either Np647–ExCys1 (black bars) or Np647–ExScra (white
bars). Data are mean+SEM (n=3 mice per condition). **p<0.01 and
***p<0.001 vs Np647–ExCys1
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excess of free exendin and (3) after the selective deletion of
the insulin-producing cells. The pancreatic uptake of our
probe was decreased by about 74% after the near-total loss
of insulin in male RIP-DTr mice, which provides a larger
imaging change than that recently reported in another model
(about 25%) [30]. What causes the residual signal seen in
these animals remains to be determined and may be
attributable to the longer persistence of the nanoparticles in
the blood circulation and/or their uptake by pancreatic im-
mune cells of the diabetic mice. We further document that,
despite the limited sensitivity of clinical MRI, the accumula-
tion of the probe was sufficient to modify T2-weighted mag-
netic resonance images of the murine pancreas and an iron












Fig. 3 Fluorescence microscopy
of control RIP-DTr pancreas
sections 24 h after the intravenous
injection of either Np647–
ExCys1 (a) or Np647–ExScra
(b). Fluorescent nanoparticles are
seen in red and the pancreas
sections were stained for insulin
(blue) and glucagon (yellow/
orange). The white box outlines
the area that is shown at a higher
magnification in the right merge
panel. Scale bar, 30 μm in all
panels, except for 10 μm in the
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Fig. 4 (a, b) T2measurements before (baseline), immediately after (t=0)
and 24 h after the intravenous injection of either Np647–ExCys1 (a) or
Np647–ExScra (b). Symbols show successive measurements in the same
mice vs baseline value, **p<0.01 and ***p<0.001. (c) Representative
greyscale T2-weighted magnetic resonance images of male RIP-DTr
mice. A colour-coded T2 map (scale in ms on the left) is superposed on
the greyscale magnetic resonance images. (d) Pancreatic probe accumu-
lation in control RIP-DTr mice 24 h after the intravenous injection of
either Np647–ExCys1 or Np647–ExScra. The probe accumulation is
given by [loge (T2baseline/T224 h)]. Mean values are shown by the lines.
***p<0.001 vs Np647–ExCys1
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30]. Most significantly, we show here that this approach
allowed for the repeated monitoring and quantitative evalua-
tion of both maximal and submaximal losses of insulin as
experimentally induced in a mouse model of cell-specific
deletion [33, 36]. Thus, the probe allowed differentiation of
the major loss of insulin observed in male RIP-DTr mice,
which parallels that of beta cells and mimics the beta cell loss
in type 1 diabetes, from the significantly smaller loss of beta
cells and insulin observed in the female mice, which mimic
the beta cell loss anticipated in most cases of type 2 diabetes
[31]. The data provide a significant step towards the validation
of a probe monitoring the effect of candidate treatments in a
pre-clinical setting, assuming that the expression of GLP-1rs
is not altered under different glycaemic conditions [43]. Such
pre-clinical studies should further benefit from the exquisite
resolution achieved with high magnetic field MRI, which now
allows for the visualisation of individual islets within an intact
pancreas [21, 23].
Given that the data were generated using widely available
MRI equipment, they also open exciting perspectives for the
most-needed clinical imaging of patients with type 1 and
type 2 diabetes. However, whether the method could improve
the present status of human islet imaging [17, 22, 44] remains
to be determined. MRI is a non-ionising technique that pro-
vides unsurpassed anatomical images of soft tissues, which
facilitates the localisation of the signal source, but still features
a rather low sensitivity and is hardly amenable to the quanti-
fication of a signal in absolute terms. These features are almost
in direct contrast to those of nuclear imaging methods that
provide for a modest anatomical resolution, require the use of
radioactive probes and often require a co-registration by irra-
diating techniques such as computed tomography. Still, PET
and SPECT have an exquisite sensitivity and are easily ame-
nable to a precise quantitative evaluation of the signal [2, 3].
Accordingly, two recent studies using SPECT [17] and PET
[45] have shown that the pancreatic signal correlates with beta
cell mass in rodent models of diabetes. The authors of these
studies also documented a large individual variation in the
human pancreas signal [17, 44], which is consistent with the
reported variable range of human beta cell mass [46]. Such a
large interindividual variation calls for the repeated imaging of
any given animal or patient, to obtain reliable evaluations over
time. The radioactive dose used in nuclear imaging may
potentially be a limiting factor in such longitudinal studies
[8, 11, 14, 18, 19]. MRI may help to bypass this issue, as we



































Fig. 5 Pancreatic probe accumulation in male and female RIP-DTr mice
before and after DT treatment to ablate beta cells. Symbols represent
individual mice. Mean values are shown by the lines. *p<0.05 and













Fig. 6 Fluorescence microscopy
of pancreas sections 24 h after an
intravenous injection of Np647–
ExCys1 in DT-treated RIP-DTr
female (a) and DT-treated male
RIP-DTr (b) mice. Fluorescent
nanoparticles are seen in red, and
the pancreas sections were stained
for insulin (blue) and glucagon
(orange). The white box outlines
the area that is shown at a higher
magnification in the right merge
panel. Scale bar, 30 μm in all
panels, except for 10 μm in the
enlargements of the boxed areas
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differentiation of maximal from submaximal alterations in
beta cells content, and to sequentially and repeatedly image
the same animal. Still, the MRI approach requires the use of
contrast-enhancing agents ([21, 22, 30, 47], this study) to
enhance the endocrine signal. As for the isotopes used in
nuclear medicine imaging, the acute and long-term safety of
these contrast-enhancing agents should be carefully evaluated
[48, 49]. Furthermore, it remains to be determined whether
MRI (as well as SPECT and PET) could detect, in the same
individual or animal, smaller beta cell variations that those we
reported here (about 50% in female RIP-DTr mice), which
may be particularly important for the evaluation of new can-
didate treatments aimed at increasing the beta cell mass. Thus,
no approach is presently fully specific for beta cell imaging.
Multimodal imaging should be favoured to complement and
coordinate the positive features of different methods, and a
repeated longitudinal analysis of any given patient will most
likely be required to obtain useful estimates of beta cell mass
and function.
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